在帕金森病中使用多巴胺激动剂单疗法
1Department of Neurology, University of Birmingham, Birmingham, UK. c.e.clarke@bham.ac.uk
Lancet (London, England)
|December 14, 2002
概括
与勒沃多巴相比,多巴胺激动剂单一治疗可能会减缓帕金森病的进展,但需要进一步的研究来确定治疗策略的最终指导.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床神经学 临床神经学
背景情况:
- 利沃多巴是帕金森病的标准治疗方法,但会导致运动并发症,可能是神经毒性.
- 多巴胺激动剂越来越多地被用作初始单一疗法,但它们的长期效果和潜在的神经保护性质仍在争论中.
- 像PET和SPECT等先进的成像技术提供了对多巴胺基神经元完整性的洞察.
研究的目的:
- 评估多巴胺激动剂单一治疗与利沃多巴在早期帕金森病的潜在神经保护作用.
- 用成像生物标志物比较多巴氨基神经元损失的速度,在接受激动剂或利沃多巴治疗的患者中.
- 审查临床证据关于与激动剂相比levodopa治疗相关的疗效,安全性和生活质量.
主要方法:
- 随机对照试验比较多巴胺激动剂 (pramipexole, ropinirole) 与利沃多巴在早期帕金森病患者.
- 使用123I-β-CIT SPECT和18F-DOPA PET成像来评估条状多巴胺基神经元的完整性.
- 分析了临床结果,包括运动功能,非自愿运动,不良事件和生活质量.
主要成果:
- 与勒沃多巴相比,SPECT和PET研究表明,与普拉米克索尔或罗皮尼罗尔治疗的患者的条纹吸收损失显著减少.
- 激素单一治疗延迟了非自愿运动的开始,但导致了较差的运动控制和更多的不良事件.
- 生命质量数据显示,四年后,普拉米佩克索尔和利沃多巴之间没有显著差异,激动剂的价格更高.
结论:
- 有证据表明,多巴胺激动剂单一治疗可能提供神经保护,或者说勒沃多巴是神经毒性,尽管存在方法论上的批评.
- 目前的数据支持对运动并发症风险较小的帕金森氏症年轻患者的激素单疗法.
- 对于大多数患者来说,缺乏明确的指导,大规模的长期实用性试验对于确定最佳治疗策略至关重要.
更多相关视频
09:16A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
相关概念视频
Classification of Skeletal Muscle Relaxants
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
